Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss... Show more
Hims & Hers Health's third-quarter 2026 results land at a pivotal moment for the telehealth company. After a period of rapid expansion driven by its weight-loss franchise and an international push, investors were watching closely to see whether top-line momentum could be sustained without sacrificing profitability. The quarter highlighted a fundamental tension: revenue continues to grow quickly, but the shift toward costlier branded obesity medications has compressed gross margins. With the company also navigating a recent distribution agreement with Eli Lilly for weight-loss drugs, this report offers an early read on how management is balancing growth against margin discipline and what that means for its path back to profitability.
Hims & Hers Health reported third-quarter 2026 revenue of $890.4 million, a 49% increase from $599 million in the same period last year, but slightly below the consensus estimate of about $892.9 million. The company posted a GAAP net loss of $0.14 per share, compared with earnings of $0.06 per share a year earlier and analyst expectations of a roughly $0.06 profit. Net loss for the quarter was $33 million, versus net income of $15.8 million in the prior-year period.
Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose to $82.4 million from $78.4 million a year ago. However, gross margin fell to 57% from 74% a year earlier. Subscribers grew 13% year over year to nearly 2.8 million, while monthly revenue per average subscriber increased 30% to $105. U.S. revenue rose 21% to $657.1 million, and international revenue more than quadrupled to $233.3 million.
For the fourth quarter, the company guided revenue of $875 million to $895 million, below the roughly $953 million analysts expected. Full-year 2026 revenue guidance was narrowed to $3.13 billion to $3.15 billion, versus a consensus of about $3.21 billion, and full-year adjusted EBITDA guidance was reduced to $257 million to $277 million.
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Hims & Hers Health across a broader industry landscape, the tool can help identify comparable opportunities and emerging setups with less effort.
Hims & Hers Health shares declined roughly 2% in volatile after-hours trading following the report, as the earnings miss and softer-than-expected guidance overshadowed continued revenue growth. Investors appeared focused on two concerns: the surprise swing to a quarterly loss and the trimmed full-year outlook, particularly the reduction in adjusted EBITDA guidance. The sharp contraction in gross margin reinforced worries that the shift toward branded weight-loss drugs, while expanding revenue, is squeezing the economics of the business. Sentiment entering the report had been mixed, given recent share-price volatility, and the guidance cut gave little reason for optimism in the immediate aftermath.
Looking ahead, the central question for Hims & Hers Health is whether the margin pressure tied to branded weight-loss drugs proves temporary or structural. Investors will be watching whether gross margin stabilizes as the company scales its newer product lines and realizes operating leverage from its growing subscriber base.
International expansion remains a bright spot, with revenue more than quadrupling year over year, but it also carries upfront costs that could weigh on profitability in the near term. The recently announced distribution agreement with Eli Lilly is another key catalyst to monitor, as it may reshape the company's weight-loss product mix and its long-term margin profile.
Finally, watch subscriber growth and monthly revenue per average subscriber as leading indicators of demand. While subscribers increased 13% year over year, sequential trends and retention will signal whether the platform can sustain its growth trajectory without relying on higher-cost product categories. Management's ability to balance rapid expansion against disciplined spending will likely remain the defining theme through the remainder of fiscal 2026.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a company, which is involved in real estate investment trusts
Industry PharmaceuticalsGeneric